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Trafficking of the water channel aquaporin-2 to the apical
plasma membrane of the collecting duct is mediated by
arginine vasopressin, rendering the cell permeable to water.
We recently identified a novel form of aquaporin-2 that is
phosphorylated at serine-269 (pS269-AQP2). Using
antibodies specific for this form of the water channel, we
detected rat and mouse pS269-AQP2 in the connecting
tubule and throughout the collecting duct system.
Using confocal immunofluorescence microscopy with
organelle-specific markers and immunogold electron
microscopy, we found that pS269-AQP2 was found only on
the apical plasma membrane of principal cells. In
vasopressin-deficient Brattleboro rats, pS269-AQP2 was
undetectable but dramatically increased in abundance after
these rats were treated with [deamino-Cys-1, d-Arg-
8]vasopressin (dDAVP). This increase occurred only at the
apical plasma membrane, even after long-term dDAVP
treatment. Following dDAVP there was a time-dependent
redistribution of total aquaporin-2 from predominantly
intracellular vesicles to the apical plasma membrane,
clathrin-coated vesicles, early endosomal compartments, and
lysosomes. However, pS269-AQP2 was found only on the
apical plasma membrane at any time. Our results show that
S269 phosphorylated aquaporin-2 is exclusively associated
with the apical plasma membrane, where it escapes
endocytosis to remain at the cell surface.
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Renal water permeability of the mammalian collecting duct is
regulated by arginine vasopressin (AVP), which is released
from the posterior pituitary gland in response to increased
plasma osmolality or a reduction in the effective circulating
blood volume. The antidiuretic effect of AVP is mediated by
the binding of AVP to the type 2 vasopressin receptor in the
basolateral membrane of the collecting duct (CD) principal
cell. Acutely, this results in the translocation of intracellular
vesicles containing aquaporin-2 (AQP2) to the apical plasma
membrane, rendering the cell permeable to water.1
A critical event in AVP-mediated translocation of AQP2 to
the apical plasma membrane is phosphorylation of the C-
terminal tail of AQP2 at serine 256 (S256). This is
demonstrated in in vitro cell culture systems2–4 and in
experimental animal models.5,6
In addition to S256, phospho-proteomic analysis of native
rat inner medullary CD (IMCD) cells determined that S256 is
part of a polyphosphorylated region in the COOH terminal
tail of AQP2.7 This region contains four AVP-regulated
phosphorylation sites, namely S256, S261, S264, and S269.
Within the principal cell, pS261-AQP2 and pS264-AQP2 are
localized at different intracellular regions8,9 and are diversely
regulated by AVP. However, recent studies failed to show a
direct role for S261 phosphorylation in AQP2 trafficking.10
In this study, we examined the cellular and subcellular
localizations and AVP-mediated regulation of AQP2 phos-
phorylated at S269 (pS269-AQP2). We found that pS269-
AQP2 was localized exclusively in the apical plasma
membrane of connecting tubule (CNT) cells, CD principal
cells, and IMCD cells. In addition, chronic or acute AVP
administration in vivo regulates the extent of S269-AQP2
phosphorylation. We propose that S269 phosphorylation is
critical for the apical plasma membrane retention of AQP2
after AVP-stimulated trafficking.
RESULTS
Cellular and subcellular distribution of pS269-AQP2
Distribution of pS269-AQP2 was determined by the immuno-
histochemistry of the normal rat and mouse kidney sections.
In both species, pS269-AQP2 labeling was observed within
CD cells (Figure 1a–f). Labeling intensity was strongest in
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cortical and medullary CDs, with little labeling associated
with IMCD. In all labeled tubules, staining was only
associated with the apical plasma membrane (Figure 1,
insets). No basolateral staining was observed in any region of
the kidney.
A complete absence of labeling in AQP2 knockout mice as
compared with control (Figure 2a and b) confirmed the
specificity of the anti-pS269 antibody for AQP2. To
demonstrate that for both immunohistochemistry, and that
at the concentration used in our studies, the anti-pS269
antibody was specific for pS269-AQP2, we performed a
number of immunostaining controls. Pre-absorption of
pS269-AQP2 with a synthetic pS269-AQP2 phosphopeptide
completely abolished labeling (Figure 2d). In contrast, pre-
absorption with either a synthetic non-phosphorylated
peptide (Figure 2c) corresponding to the same region or a
pS264-AQP2 phosphopeptide (Figure 2e) did not affect
pS269-AQP2 labeling. In addition, phosphatase treatment of
rat kidney sections in vitro resulted in a reduction in pS269-
AQP2 labeling (Figure 2f and g). Taken together, these results
indicate that the staining of the apical plasma membrane
observed in rat and mouse is specific for pS269-AQP2.
Double immunofluorescence labeling with a marker for
the CNT, calbindin (Figure 3a) showed that pS269-AQP2 is
detected at low levels in CNT. Double labeling with the
intercalated cell marker Hþ -ATPase showed that within the
CD, pS269-AQP2 is restricted to principal cells (Figure 3b).
Double immunofluorescence labeling with an NH2-terminus
total AQP2 antibody showed partial colocalization (Rtotal
0.37±0.06) between pS269-AQP2 and total AQP2 in all CDs
(Figure 3c–e). In contrast to pS269-AQP2, total AQP2 was
more broadly distributed (Figure 3f) with prominent
intracellular labeling and some basolateral staining observed.
In all tubules, colocalization with pS269-AQP2 (Figure 3g)
was restricted to the apical plasma membrane region
(Figure 3h).
Immunogold electron microscopy of normal Wistar rat
kidney sections demonstrated that in CD principal cells,
pS269-AQP2 was restricted to the apical plasma membrane
(Figure 4a). In all cells, gold particles are observed only in
association with the plasma membrane (Figure 4a, inset).
After short-term [deamino-Cys-1, d-Arg-8]-vasopressin
(dDAVP) treatment (30 min), we observed a marked increase
in pS269-AQP2 labeling in the apical plasma membrane
(Figure 4b). After dDAVP treatment for this time period, all
gold particles were in direct association with the apical
plasma membrane (Figure 4b, inset). Under both conditions
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Figure 1 | Immunoperoxidase labeling of pS269-AQP2 in the
normal rat and mouse kidney. Labeling of pS269-AQP2 is
observed throughout the collecting duct of normal rat kidney
cortex (a), the inner stripe of outer medulla (b), and the inner
medulla (c). A similar distribution is seen in the mouse kidney
cortex (d), the inner stripe of outer medulla (e), and the inner
medulla (f). Labeling is predominantly observed in the apical
plasma membrane. Scale bar¼ 20mm. CD, collecting duct; IMCD,
inner medullary collecting duct; pt, proximal tubule; T, thick
ascending limb.
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Figure 2 | Specificity of pS269-AQP2 antibody. In AQP2
knockout mice, (b) there is a complete absence of
immunoperoxidase labeling with the pS269-AQP2 antibody as
compared with controls (a), indicating that the pS269-AQP2
antibody is specific for AQP2. Pre-absorption of anti-pS269 with
pS269 peptide (d) resulted in the elimination of labeling in CD. In
contrast, pre-incubation with either a non-phosphorylated
peptide corresponding to the same region (c) or a peptide
corresponding to pS264-AQP2 (e) did not affect labeling,
indicating specificity of the antibody for pS269-AQP2. Labeling of
pS269-AQP2 after phosphatase treatment of rat kidney serial
sections (g) was dramatically reduced as compared with control
(f). Scale bar¼ 20mm.
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examined, we never observed gold particles in association
with the basolateral membrane (Figure 4c). These results
suggest that there is a large increase in pS269-AQP2
abundance after dDAVP exposure (see later).
To further define the subcellular distribution of pS269-
AQP2, double immunofluorescence labeling was performed
with anti-pS269 and a variety of established subcellular
markers. No colocalization was observed with the basolateral
membrane marker E-cadherin, the medial Golgi marker
GS28, the cis-Golgi matrix marker GM130, the cis-Golgi
marker p115, the trans-Golgi network marker Vti1a, the early
endosome marker EEA1, and the lysosomal marker Cathe-
psin D (Figure 5, Table S1). Although a small degree of
colocalization was observed with the clathrin-coated vesicle
marker Adaptin-b (Figure 5g) in some apical regions of the
cell, numerous Adaptin-b-positive, but pS269-AQP2-nega-
tive compartments were observed at the apical plasma
membrane. These results confirm that pS269-AQP2 resides
only in the apical plasma membrane domain.
Effect of short-term vasopressin treatment on pS269-AQP2
Normal Wistar rats or AVP-deficient Brattleboro rats were
treated for 30 min with the V2-selective vasopressin analog
dDAVP to determine the effects of short-term AVP treatment
on pS269-AQP2 abundance. Semiquantitative immuno-
blotting on inner medulla protein homogenates showed that
the total abundance of AQP2 was not significantly changed in
response to dDAVP treatment (Figure 6). Conversely, pS269-
AQP2 abundance increased significantly in response to
treatment, indicating that phosphorylation of AQP2 at this
site is regulated acutely by AVP in vivo. Surprisingly, in
addition to 29 kDa non-glycosylated form of AQP2, in Wistar
rats, the anti-pS269 antibody detected an additional band at
approximately 32 kDa. The molecular identity of this higher-
molecular-weight moiety is currently unknown. It could
represent a form of AQP2 that has been chemically modified,
for example by ubiquitination,11 but the small-molecular-
weight change makes this unlikely. In non-stimulated
Brattleboro rats, there was a complete absence of pS269-
AQP2 immunoreactivity. These results were confirmed by
immunohistochemistry on kidney sections from Brattleboro
rats treated with either vehicle or dDAVP for 20 min. In
vehicle-treated animals, no pS269-AQP2 labeling was de-
tected in the cortex, ISOM, or IMCD (Figure 7a–c). Strong
apical labeling was observed in all CDs after dDAVP
treatment (Figure 7d–f). For comparison, labeling of
pS256-AQP2 was performed under similar conditions
(Figure 7g–l). Strong intracellular labeling of pS256-AQP2
is observed in control conditions. After 20 min dDAVP
treatment, pS256-AQP2 labeling intensity increases predo-
minantly in the apical plasma membrane. Taken together,
these results suggest that pS269-AQP2 is dependent on the
presence of AVP and that AVP increases pS269-AQP2 only at
the apical plasma membrane.
Our earlier studies determined that pS264-AQP2 is
observed in both the apical plasma membrane and
intracellular compartments associated with the early endo-
cytic pathway after dDAVP treatment. To examine whether a
similar mechanism existed for pS269-AQP2, Brattleboro rats
were treated with a single intravenous injection of vehicle or
dDAVP, and after 15 or 60 min, kidneys were perfusion fixed.
Double immunofluorescence labeling showed no colocaliza-
tion of pS269-AQP2 with EEA1-positive compartments or
Cathepsin-D-positive compartments at both time points
examined (Figure 8). In contrast, total AQP2 was observed in
association with clathrin-coated vesicles, early endocytic
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Figure 3 | Confocal laser scanning microscopy of pS269-AQP2 in normal rat kidney. (a) Double immunofluorescence labeling of pS269-
AQP2 (green, inset) and calbindin (red) identified that pS269-AQP2 is weakly expressed in connecting tubules. (b) Double
immunofluorescence labeling of pS269-AQP2 (green) and [Hþ ]ATPase (red) determined that pS269-AQP2 is expressed in collecting duct
principal cells. pS269-AQP2 (green, c) and total AQP2 (red, d) colocalize (yellow, e) at the apical plasma membrane of the collecting duct. At
higher magnification, total AQP2 (f) is observed both on membranes and intracellularly. Colocalization with pS269-AQP2 (g) is restricted to
the apical plasma membrane (h). CD, collecting duct; CNT, connecting tubule. Scale bar¼ 20 mm.
Kidney International (2009) 75, 295–303 297
HB Moeller et al.: Regulation of AQP2 S269 phosphorylation o r i g i n a l a r t i c l e
compartments, and lysosomal compartments after AVP
stimulation (Figure 8). The localization of AQP2 to these
compartments was confirmed by immunogold electron
microscopy (Figure 9). Furthermore, immunogold electron
microscopy using an antibody directed against the NH2-
terminus of AQP2 confirmed the localization of AQP2 in
lysosomes (Figure S1).
Long-term AVP treatment resulted in increased pS269-
AQP2 in the apical plasma membrane domain. To examine
whether the increased pS269-AQP2 abundance observed after
short-term dDAVP treatment was also present in response to
long-term AVP stimulation, Brattleboro rats were adminis-
tered either vehicle or dDAVP for 5 days by osmotic
minipumps, and kidney sections were labeled with anti-
pS269-AQP2. Confirming our earlier observation, pS269-
AQP2 labeling is absent under control conditions (Figure
10a). Strong apical labeling is observed in response to
continuous infusion of dDAVP (Figure 10b). Similarly, in
Wistar rats water loaded for 5 days, pS269-AQP2 labeling is
almost absent, whereas rats water-restricted for a similar time
period showed strong apical labeling of pS269-AQP2 (Figure
10c–d).
DISCUSSION
In the mammalian kidney, AVP regulates the trafficking of
AQP2-containing intracellular vesicles to the apical plasma
membrane of the CD. This is a critical event for increasing
the water permeability of the CD and producing concen-
trated urine. Phosphorylation of S256 in the COOH-terminal
tail of AQP2 is essential for the membrane accumulation of
AQP2.2–4 In addition to S256, the COOH-terminal tail is
phosphorylated at S261, S264, and S269. In our recent
studies, we determined that two of the phosphorylated forms
of AQP2, pS261-AQP2 and pS264-AQP2, are associated with
different intracellular compartments,5,8 although recent
studies suggest that the phosphorylation status of AQP2 at
S261 does not alter constitutive or regulated trafficking of
AQP2.10 In this study, we show that pS269-AQP2 is
associated only with the apical plasma membrane domains
of the CD, providing additional evidence that phosphory-
lated forms of AQP2 are localized to different cellular
compartments, and further suggesting that dynamic poly-
phosphorylation of AQP2 may be important for regulating
AQP2 intracellular distribution.
A complete absence of labeling in CD-specific AQP2
knockout mice, as well as abolished labeling of kidney
sections after pre-incubation of the antibody with a pS269
synthetic peptide, confirmed specificity of the antibody for
pS269-AQP2. These data corroborate our previous observa-
tion regarding antibody specificity.12
A variety of immunolocalization techniques showed that
pS269-AQP2 is associated only with apical plasma membrane
domains throughout the CNT and CD. Unlike earlier
observations of total AQP2,13,14 we never observed the
association of pS269-AQP2 with the basolateral membrane.
These results are supported by in vitro cell culture studies. In
MDCK cells stably transfected with a mutant AQP2
mimicking the charge state of pS269-AQP2 (S269D), AQP2
is localized to the plasma membrane under non-stimulated
conditions.12 Taken together, our data suggest that phos-
phorylation at S269 is involved with the apical targeting of
AQP2.
In our earlier studies, we have shown that AVP can
regulate acutely the degree of phosphorylation at each of the
four serine residues at the COOH terminus tail of AQP2.7,12
In this study, we find that acute dDAVP administration to
rats in vivo recapitulates our previous in vitro findings. After
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Figure 4 | Immunoelectron microscopy of pS269-AQP2 in the
normal rat kidney. (a) In normal Wistar rat kidney collecting duct
principal cells, pS269-AQP2 (arrows) is observed in the apical
plasma membrane domain (apm). At high magnification (inset), it
is clear that all gold particles are associated with the membrane.
(b) After dDAVP treatment (30 min), the number of gold particles
increases in the apical plasma membrane domain (arrows), and at
high magnification (inset), it is clear that all gold particles are
associated with the membrane and no intracellular gold particles
can be observed. (c) After dDAVP treatment, no gold particles are
associated with the basolateral membrane. L, lateral membrane;
N, nucleus.
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30 min of dDAVP administration, pS269-AQP2 abundance
increased in two different animal models. Immunohisto-
chemistry determined that the increased pS269-AQP2
abundance occurred exclusively at the apical plasma mem-
brane. Unlike pS256-AQP2, pS269-AQP2 was not observed
in the absence of AVP, indicating that AVP is essential for
phosphorylation at this site. Long-term AVP treatment
resulted in a similar distribution of pS269-AQP2.
We have shown earlier that in the CD, there is time-
dependent redistribution of pS264-AQP2 in response to
dDAVP stimulation from predominantly intracellular vesicles
to both the basolateral and apical plasma membranes.8,9 In
addition, a proportion of pS264-AQP2 can be observed in
early endosomal and recycling compartments. A major
finding in this study is that pS269-AQP2 is always associated
with the apical plasma membrane. pS269-AQP2 is never
observed in EEA1-positive vesicles, Rab11-positive recycling
vesicles, or Cathepsin D-positive lysosomes. In addition,
although a small proportion of pS269-AQP2 colocalizes with
Adaptin-b positive compartments, we observed numerous
distinct Adaptin-b positive, pS269-AQP2-negative compart-
ments. This suggests that pS269-AQP2 could potentially
‘escape’ endocytosis and remain at the cell surface. These
results for pS269-AQP2 may explain a earlier observation
that a proportion of total AQP2 is located in ‘endocytosis-
resistant’ membrane domains after AVP treatment.15 Another
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Figure 5 | Subcellular distribution of pS269-AQP2 in normal rat kidney collecting duct. For all images, pS269-AQP2 is depicted in
green, intracellular markers are depicted in red, and overlaid images show colocalized pixels in yellow. Insets in each panel represent high-
magnification images of selected areas, with arrows indicating pS269-AQP2 and arrowheads for specific intracellular markers. No
colocalization is observed with the basolateral membrane marker E-cadherin (a), the medial Golgi marker GS28 (b), the cis-Golgi matrix
marker GM130 (c), the cis-Golgi marker p115 (d), the trans-Golgi network marker Vti1a (e), the early endosome marker EEA1 (f), and the
lysosomal marker Cathepsin D (h). A small degree of colocalization is observed with the clathrin-coated vesicle marker Adaptin-b at the
apical plasma membrane, but distinct Adaptin-b-positive compartments are also observed (g). See Supplementary Table 1 for statistical
comparison. Scale bar¼ 20mm.
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Figure 6 | Short-term vasopressin treatment increases
abundance of pS269-AQP2 in vivo. Immunoblots of inner
medulla homogenates from Wistar rats and Brattleboro rats
treated with dDAVP for 30 min. Each lane represents a sample
from a different rat. Values are mean band densities (±s.e.)
normalized such that the mean for the control rats is defined as 1.
In Brattleboro rats, under control conditions pS269-AQP2 is not
detectable, thus the mean band density value is arbitrary.
Abundance of total AQP2 is not significantly changed after dDAVP
treatment, whereas pS269-AQP2 abundance increases
significantly. Immunoblotting using actin confirmed equal
loading. *Significant change in mean band densities between
groups.
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explanation for our results is that the fraction of AQP2 that is
endocytosed from the plasma membrane is immediately
dephosphorylated at S269. Further studies utilizing cell
models are required to elucidate these possibilities. In
contrast to pS269-AQP2, using both confocal microscopy
and immunogold electron microscopy, we detected total
AQP2 in clathrin-coated vesicles, early endosomes, and
lysosomes in CD principal cells after AVP treatment. Our
finding that, using antibodies targeted against both the N and
C termini, a proportion of total AQP2 localizes to lysosomes
is novel and in contrast to earlier observations.16 Our results
provide evidence for a pathway of AQP2 degradation in CD
principal cells.
The AVP-regulated accumulation of AQP2 at the apical
plasma membrane is believed to be because of both an
increased rate of exocytosis and decreased endocytosis.17–19
In principle, phosphorylation of S269 could influence either
process. From our results described here, and our previous
observation that a mutant AQP2 mimicking the charge state
of S269-AQP2 (S269D) is localized to the plasma mem-
brane,12 we propose that S269 phosphorylation is a
mechanism that inhibits AQP2 endocytosis by allowing the
protein to be sequestered in the plasma membrane or held
out of clathrin-mediated endocytosis. Recent studies by
Kamsteeg et al.11 demonstrated conclusively that AQP2 is a
short chain ubiquitinated at position K270 and that
ubiquitination of AQP2 increases its rate of endocytosis.
Theoretically, S269 phosphorylation may regulate the degree
of ubiquitination and thus regulate its endocytosis. Future
studies using cell-based models will be required to examine
this hypothesis. Alternatively, as S269 is located in a putative
type I PDZ ligand domain (SKA) at the C terminus of AQP2,
S269 phosphorylation may alter the efficiency of binding of
AQP2 to PDZ domain-containing proteins,20,21 many of
which are expressed in the IMCD.22 The consensus class I
PDZ ligand motif (-S/T-X-f, where f is any hydrophobic
amino acid) is conserved in AQP2 from all mammalian
sequences to date, with only a conserved S versus T variation
at the -3 position relative to the COOH-terminus in humans.
This high degree of conservation between species makes it
highly likely that this motif plays some role in the interaction
of AQP2 with other proteins at the plasma membrane. Future
studies will be required to determine whether modification of
this motif can influence the plasma membrane localization of
AQP2.
MATERIALS AND METHODS
Materials
An affinity-purified rabbit polyclonal antibody (anti-pS269) was
generated against a proprietary sequence from the COOH terminus
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Figure 7 | Short-term vasopressin exposure increases pS269-AQP2 abundance in the apical plasma membrane. Brattleboro rats were
treated with either vehicle or dDAVP for 20 min and kidneys sections labeled with anti-pS269. Under control conditions, no labeling is
apparent in the cortex (a), the inner stripe of outer medulla (b), and the inner medulla (c), whereas strong apical labeling (arrows) is
observed in response to dDAVP (d–f, and insets). In contrast, pS256-AQP2 is observed in all regions under control conditions (g–i,
arrowheads) and labeling intensity increases predominantly in the apical plasma membrane in response to dDAVP treatment (j–l, and
insets). Scale bar¼ 20mm. CD, collecting duct; IMCD, inner medullary collecting duct.
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of rat AQP2 that included pS269 (PhosphoSolutions, Aurora, CA,
USA). Initial characterization of the anti-pS269 antibody deter-
mined that the antibody was specific for the pS269-AQP2 isoform.12
In addition, a total AQP2 antibody against the N terminus (N-20,
Santa Cruz, CA, USA) of rat AQP2, a total AQP2 antibody
corresponding to amino acids in the COOH terminus upstream
from the polyphosphorylated region of rat AQP2,12 an affinity-
purified antibody anti-pS256, which recognizes AQP2 phosphory-
lated at Ser-256,23 and an affinity-purified antibody against b1-
[Hþ ]ATPase24 were used. Commercial antibodies used were mouse
monoclonal antibodies against calbindin D-28K (Research Diag-
nostics, Concord, MA, USA), E-cadherin (BD Biosciences, Franklin
Lakes, NJ, USA), early endosome-associated protein (EEA1), Golgi
SNARE 28 (GS28), p115, Vti1a, Adaptin-b, (all from BD Transduc-
tion Laboratories, Franklin Lakes, NJ, USA), and a goat polyclonal
antibody against Cathepsin D (Research Diagnostics).
Phosphatase treatment: Dephosphorylation of paraffin-embedded
sections using calf intestinal alkaline phosphatase (Sigma, Brondby,
Denmark) was performed as described earlier,25 with minor
modifications. After blocking of free aldehyde groups, sections were
rinsed five times in alkaline phosphatase buffer (100 mM Tris, 50 mM
CaCl2, 0.1 mM MgCl2, 8.4 mM leupeptin, 4 mM Pefablock, pH 9.0).
Later, the sections were incubated in alkaline phosphatase buffer
with or without calf intestinal alkaline phosphatase (B130 units/ml)
in a water bath with constant agitation at 35 1C for 2.5 h.
Animal studies
All animal protocols were approved by the boards of the Institute of
Anatomy and Institute of Clinical Medicine (University of Aarhus)
in accordance to the licenses for the use of experimental animals
issued by the Danish Ministry of Justice.
Protocol 1. Normal Wistar rats, normal C57/BL6J mice, and
CD-specific knockout mice. CD-specific knockout mice and wild-type
controls were obtained from an in-house stock.26 Animals were
maintained on standard rodent diet and had free access to water.
Kidneys were perfusion fixed with 3% paraformaldehyde in 0.1 M
sodium cacolydate, and pH 7.4 after anesthesia with isoflurane.
Protocol 2. Short-term dDAVP infusion of Wistar rats. Before
the experiment, rats had free access to water and standard rat chow.
Four rats were treated with subcutaneous injections of 1 ng dDAVP
(Sigma-Aldrich, Brondby, Denmark) in 200 ml saline per animal, and
four vehicle-injected rats served as controls. After 30 min, rats were
anesthetized and kidneys were perfusion fixed. Between dDAVP
injection and perfusion fixation rats had free access to water but not
food.
Protocol 3. Short-term dDAVP infusion of Brattleboro rats.
Homozygous Brattleboro rats deficient in AVP were maintained on
standard rat chow with free access to water. Eight rats were treated
with intravenous injection of 1 ng of dDAVP in 200 ml saline per
animal, and eight saline-injected rats served as controls. The rats
(four rats for each group) were anesthetized after 15 or 60 min and
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Figure 8 | pS269-AQP2 is not associated with early endosomes or lysosomes after short-term dDAVP administration. Brattleboro
rats were treated with either vehicle or dDAVP (15 and 60 min) and double immunofluorescence labeling was performed. Labeling of AQP2
is depicted in green and subcellular markers in red. Colocalization is indicated by a yellow pseudocolor and thin arrows. Arrowheads
indicate distinct vesicles labeled with subcellular markers. Thick arrows indicate distinct AQP2-containing vesicles. pS269-AQP2 and
EEA1-positive vesicles were not associated after vehicle, 15, or 60 min of dDAVP treatment (a, b, and c). In contrast, total AQP2 and
EEA1-positive vesicles colocalized either under control conditions (d) or after 60 min of dDAVP treatment (f), but not after 15 min of dDAVP
administration (e). Zero colocalization was observed between anti-pS269 and Cathepsin D at all time points (g, h, and i). Under control
conditions or after 15 min dDAVP, no colocalization was observed between total AQP2 and Cathepsin D (j). After 60 min of treatment,
although distinct AQP2-containing vesicles and Cathepsin D-positive vesicles were apparent (l), a proportion of AQP2 colocalized with
Cathepsin D (m).
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kidneys were perfusion fixed as described above. Between injection
of dDAVP and fixation of the kidney, the 60-min group had free
access to water but not food. The 15-min group was kept under
anesthesia.
Protocol 4. Long-term dDAVP infusion of Brattleboro rats.
Before experiments, rats had free access to standard rodent diet
and water. Rats (six for each group) were implanted subcutaneously
with osmotic minipumps (Alzet, Cupertino, CA, USA) delivering
either 5 ng/h dDAVP or isotonic saline. After 5 days, the rats were
anesthetized by halothane and kidneys were perfusion fixed.
Protocol 5. Water loading/restriction of Wistar rats. Rats were
kept in metabolic cages and fed a gelled diet containing either 15 ml
water (water restricted) or 45 ml water (water loaded) as described
earlier.27 After 5 days, rats were anesthetized and kidneys perfusion
fixed.
Preparation of tissue for immunogold electron microscopy
Fixed tissue blocks from the kidney inner medulla were infiltrated
with 2.3 M sucrose for 30 min and frozen in liquid nitrogen. Frozen
tissue blocks were subjected to cryosubstitution and Lowicryl HM20
embedding. Lowicryl sections of 80 nm were cut on a Reichert
Ultracut S and were pre-incubated with 0.05 M Tris, pH 7.4, 0.1%
Triton X-100 (TBST) containing 0.1% sodium borohydride and
0.05 M glycine followed by incubation with TBST containing 0.2%
skimmed milk. Pre-incubation was followed by incubation with
anti-pS269 (1:250 dilution) and labeling was visualized with
goat anti-rabbit IgG conjugated to 10-nm colloidal gold particles.
Grids were stained with uranyl acetate for 10 min and with lead
citrate for 5 s.
Semiquantitative immunoblotting
Preparation of protein samples, sodium dodecyl sulfate polyacry-
lamide gel electrophoresis and immunoblotting were performed as
described earlier.13 Antibodies used were affinity-purified anti-
pS269 (1:250 dilution), anti-AQP2 (N-20, 1:2000 dilution), and
b-actin (Sigma, 1:5000 dilution). Quantitative data are presented as
mean±s.e. Data were analyzed by one-way analysis of variance
followed by Bonferroni’s multiple-comparisons test. Multiple-
comparisons tests were only applied when a significant difference
was determined in the analysis of variance (Po0.05). P-values
o0.05 were considered statistically significant.
Immunolabeling of kidney sections
This technique has been described in detail earlier.13 Representative
images from a minimum of four animals for each condition are
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Figure 9 | Total AQP2 is associated with clathrin-coated
vesicles, early endosomes, and lysosomes. Brattleboro rats
were treated with dDAVP for 60 min and immunogold electron
microscopy was performed using an antibody targeted against
the N terminus of rat AQP2. (a) In collecting duct principal cells,
total AQP2 (large gold particles) is observed in the apical plasma
membrane domain (arrows) and intracellularly (arrowheads). In
some regions, AQP2 is associated with the clathrin-coated vesicle
marker Adaptin-b (small gold particles, small arrows) at the apical
plasma membrane (I) and in distinct subapical vesicles (II). Total
AQP2 is also observed in early endosomes (III). (b) Total AQP2
(large gold particles) is associated with the apical plasma
membrane domain (arrows) and distinct intracellular vesicles
(arrowheads). In addition, in some regions (*), total AQP2
colocalizes with the lysosomal marker cathepsin-D (small gold
particles). At high magnification (IV), a single-distinct lysosomal
structure can be observed containing cathepsin-D (small gold
particles, arrows) and AQP2 (large gold particles, arrowheads).
apm, apical plasma membrane.
a b
c d
Figure 10 | Long-term vasopressin exposure increases pS269-
AQP2 abundance in the apical plasma membrane. Brattleboro
rats were administered either vehicle or dDAVP for 5 days by
osmotic minipumps. Under control conditions, pS269-AQP2
labeling is absent (a). Strong apical labeling is observed in
response to dDAVP (b). Similarly, in Wistar rats water loaded for
5 days (c), pS269-AQP2 labeling was absent, whereas rats water
restricted for a similar time period showed strong labeling of
pS269-AQP2 only in the apical plasma membrane (d). Insets
represent high magnification. Scale bar¼ 20mm.
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shown. Light microscopy was carried out with a Leica DMRE
microscope (Leica Microsystems, Herlev, Denmark).
Confocal laser scanning microscopy
Leica TCS SL (SP2) laser confocal microscope and Leica Confocal
Software were used for imaging of the kidney tissue sections. Images
were taken using an HCX PL APO  63 oil objective lens.
Assessment of colocalization
To quantify the degree of colocalization, high-resolution images
from different experimental rat kidney sections (at least eight images
for each condition) were obtained sequentially using a 488-nm laser
line and emission between 505 and 540 nm for Alexa 488, and a 546-
nm laser line and emission between 570 and 620 nm for Alexa 546/
555. Quantification of colocalization was performed using ImageJ
software package (colocalization threshold analysis) and visual
assessment of the staining pattern. Pearson’s correlation coefficient
(R) was used to determine the magnitude of correlation. A value of 1
represents perfect correlation; 1 represents perfect exclusion and
zero represents random localization.
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